Skip to content

Efficacy of phosphorylated pullulan in endoscopic therapy for early gastric cancer

Efficacy and safety of phosphorylated pullulan in endoscopic submucosal dissection for early gastric cancer

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1062240053
Enrollment
60
Registered
2024-09-11
Start date
2025-01-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer

Interventions

To compare the injection performance of submucosal injection agents (PPL solution vs. hyaluronic acid solution).

Sponsors

Otsuka Motoyuki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients scheduled for gastric ESD for early gastric cancer 2.Patients with early gastric cancer whose lesion diameter is 10-30mm 3.Patients with early gastric cancer whose depth of invasion is assumed to be intramucosal cancer 4.Patients who are able to obtain informed consent to participate in the study of their own free will after receiving sufficient explanation and understanding. 5.Patients aged 18 years or older and younger than 80 years at the time of obtaining consent

Exclusion criteria

Exclusion criteria: 1 Patients scheduled to have two or more lesions of early gastric cancer removed at the same time 2 Patients in whom the incision line during gastric ESD for early gastric cancer is expected to span the cardia or pylorus 3 Patients taking antithrombotic drugs 4 Patients with advanced cancer in other organs 5 Patients using medical devices such as pacemakers 6 Poorly controlled diabetic patients 7 Patients with a history of myocardial infarction 8 Patients with unstable angina 9 Serious liver disease (AST (GOT) or ALT (GPT)100 U or more) or liver cirrhosis patients 10 Patients with severe renal disease (BUN 25 mg/dL or serum creatinine 2.0 mg/dL or higher) 11 Women who are pregnant or may become pregnant 12 lactating women 13 Other patients deemed unsuitable as research subjects by the principal investigator or co-investigator

Design outcomes

Primary

MeasureTime frame
Injection time of submucosal injection

Secondary

MeasureTime frame
1. Mucosal elevation ability of PPL: Efficacy rate (rate of achieving en bloc resection with 0-1 additional injections to the same site) Mucosal elevation form (steep, gentle elevation, no elevation), Total amount of PPL injections, number of additional injections to the same site 2.PPL usage experience: Operator evaluation questionnaire (VAS scale) Ease of treatment Bubbling during treatment Caregiver evaluation questionnaire Ease of injection 3. Gastric ESD procedure results: procedure time, complete en bloc resection rate, incident rate

Contacts

Public ContactTakuya Satomi

Okayama University Hospital

tak_03_01_stm@yahoo.co.jp+81-86-235-7218

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026